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Abstract Dephosphorylation of the two key regulatory factors
of myosin light chain phosphatase (MLCP), CPI17 and MBS
(myosin binding subunit) of MLCP was studied. While Thr38
phosphorylated CPI17 is quite susceptible to protein phospha-
tases, phosphorylated MBS was highly resistant to dephos-
phorylation. Type 2A, 2B and 2C protein phosphatases (PP2A,
PP2B and PP2C), but not type 1 (PP1), dephosphorylated
CPI17. The majority of the CPI17 phosphatase activity in
smooth muscle was attributed to PP2A and PP2C. Phospholipids
inhibited dephosphorylation of MBS and arachidonic acid (AA)
inhibited PP2A activity against both MBS and CPI17, raising
the possibility that AA favors the preservation of active MLCP.
Consistently, while the phosphorylation of CPI17 was promptly
decreased when the agonist was removed, the phosphorylation of
MBS was unchanged in intact smooth muscle fiber. The results
suggest that MBS phosphorylation mediated regulation of
MLCP is not suitable for regulating rapid change in myosin
phosphorylation. On the other hand, phosphorylated CPI17 is
readily dephosphorylated thus likely to play a role in regulating
fast phosphorylation^dephosphorylation cycle in cells. ß 2002
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Motor activity of myosin II is activated by phosphorylation
at Ser19 of its regulatory light chain [1^3]. The protein kinase
responsible for the phosphorylation at this site is myosin light
chain kinase (MLCK) [1^4] but other protein kinases [5^7]
might also contribute to myosin II phosphorylation.
On the other hand, myosin light chain phosphatase
(MLCP) is regulated by various signaling pathways [8].
MLCP consists of three subunits: myosin binding subunit
(MBS), a 20 kDa small subunit (M20), and a catalytic subunit
of type 1 protein phosphatase (PP1c) [9]. MBS can be phos-
phorylated by Rho-dependent kinase [10] that results in a
decrease in MLCP activity. Therefore, it has been postulated
that an activation of the Rho signaling pathway would down-
regulate MLCP and, thus, increase myosin II activity. The
phosphorylation site responsible for the inhibition of MLCP
is Thr641 (rat sequence) [11]. MBS can also be phosphorylat-
ed by ZIP kinase [12] and myotonic dystrophy protein kinase
[13] at the inhibitory site. Activation of protein kinase C
(PKC) inhibits MLCP, thus inducing smooth muscle contrac-
tion [14], which is due to an activation of MLCP-speci¢c in-
hibitor protein, CPI17, by phosphorylation at Thr38 [15,16].
CPI17 can be phosphorylated by Rho-kinase [17] and protein
kinase N [18] at the same site; therefore the Rho pathway
may regulate MLCP via two di¡erent mechanisms, i.e.
CPI17 phosphorylation and MBS phosphorylation. However,
not much is known about the signi¢cance of these two regu-
latory components of MLCP in rapid change in myosin phos-
phorylation during the cell activation induced by external
stimuli. A key question is whether or not the phosphorylated
states of these factors are subjected to fast phosphorylation^
dephosphorylation cycling.
Nothing is known about the protein phosphatases respon-
sible for the dephosphorylation of MBS and CPI17. Since the
phosphorylation level of MBS and/or CPI17 is determined by
the relative activity of the responsible protein kinases and
phosphatases, it is critical to determine the susceptibility of
MBS and CPI17 against protein phosphatases. It is also crit-
ical to identify the MBS and/or CPI17 phosphatases for
understanding the regulatory mechanism of myosin II phos-
phorylation. Four major cellular serine/threonine-speci¢c pro-
tein phosphatases have been reported and are classi¢ed into
four types termed PP1, PP2A, PP2B (calcineurin), and PP2C
[19^21], based upon their substrate speci¢city, sensitivity to
inhibitors, and the requirement of divalent cations for their
activity [19^21]. While PP1 and PP2A have no divalent cation
requirement for their activity, PP2B is a Ca2-dependent
phosphatase that contains a calmodulin binding subunit.
PP2C is a Mg2-dependent phosphatase. In the present study,
we studied the susceptibility of MBS and CPI17 in their phos-
phorylated form against protein phosphatases and attempted
to determine the protein phosphatases responsible for the de-
phosphorylation of MBS and CPI17. The results clearly
showed that MBS is highly resistant to dephosphorylation
while CPI17 is readily dephosphorylated by protein phospha-
tases.
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2. Materials and methods
2.1. Chemicals
[Q-32P]ATP (3000 Ci/mmol) was obtained from Du Pont-NEN, Bos-
ton, MA, USA; bovine serum albumin (BSA), okadaic acid, and
phospholipids were from Sigma, St. Louis, MO, USA. All other
chemicals were of reagent grade.
2.2. Proteins
The MLC was prepared as described [22]. MLCK was puri¢ed from
frozen turkey gizzard [23]. Calmodulin was puri¢ed from bovine testis
[24]. The phosphorylated MLC by MLCK was prepared as described
[25]. The catalytic subunits of PP1 (PP1c) and PP2A (PP2Ac) were
puri¢ed from rabbit skeletal muscle [26]. PP2B was purchased from
Sigma RBI (St. Louis, MO, USA). PP2C was puri¢ed from turkey
gizzard [27]. Puri¢cation and phosphorylation of the recombinant
CPI17 were according to Eto et al. [28] and Kitazawa et al. [16],
respectively. Recombinant rabbit PKCK, Rho-kinase, and MBS
were expressed with baculovirus expression system and puri¢ed with
Ni2-NTA agarose a⁄nity chromatography [29].
2.3. Antibodies
Rabbit polyclonal antibodies against porcine CPI17, phospho-T38
porcine CPI17, phospho-T641-rat1 MBS or anti-phospho-T799-rat1
MBS were prepared as described [30,31]. The peptides,
CSKLQSPSRARGPGGSPGGLQKRGAR for CPI17, CRHARV[-
phospho-T]VKYDR for phospho-T38 CPI17, CQSRRS[phospho-
T]QGVTL for phospho-T641-rat1 MBS, or CEKRRS[phospho-
T]GVSFW for phospho-T799-rat1 MBS was chemically synthesized
and conjugated with keyhole limpet hemocyanin at the NH2-terminal
cysteine residue. The obtained anti-serum was subjected to a⁄nity-
puri¢cation with the peptide-conjugated a⁄nity column. Anti-mono-
clonal MBS antibody that recognizes the MBS regardless its phos-
phorylation states was purchased from BAbCO (Richmond, CA,
USA). Anti-phosphorylated myosin regulatory light chain antibodies
were made as described [32].
2.4. Phosphatase assays
The phosphatase assay for PP1 and PP2A was performed at 30‡C
in bu¡er containing 50 mM Tris^HCl, pH 7.0, 0.1 mM EGTA, 0.3%
BSA, 0.03% Brig-35, 0.1% 2-mercaptoethanol (2-ME) and a substrate.
The assay for PP2B was carried out at 30‡C in bu¡er containing 50
mM Tris^HCl, pH 7.0, 0.2 mM CaCl2, 1 mM MnCl2, 0.3% BSA,
0.03% Brig-35, 0.1% 2-ME and a substrate. The assay for PP2C
was performed at 30‡C in bu¡er containing 50 mM Tris^HCl, pH
7.0, 10 mM MgCl2, 100 mM NaCl, 0.1 mM EGTA, 0.3% BSA,
0.03% Brig-35, 0.1% 2-ME and a substrate. The reaction was termi-
nated by boiling with one-third volume of the stop bu¡er containing
4% sodium dodecyl sulfate (SDS), 200 mM NaF, 4 mM dithioerythri-
tol, 40 mM EDTA, and 40 mM EGTA, 0.04% BPB, and 60% glyc-
erol. The samples were subjected to SDS^polyacrylamide gel electro-
phoresis (PAGE). The phosphorylation levels were determined by the
incorporation of radioactive phosphate. The protein bands in the gels
were excised and the radioactivity was counted by a scintillation coun-
ter (Beckman LS6500, Fullerton, CA, USA). The phosphorylation
levels at the speci¢c sites were determined by Western blot using the
phosphorylation site-speci¢c antibodies as described [32] followed by
densitometry.
2.5. Isometric force measurement of rabbit femoral artery and
Western blot
New Zealand white rabbits (2.5^3.0 kg) were sacri¢ced by the in-
jection of pentobarbital (100 mg/kg). Smooth muscle strips (70 Wm
thick, 750 Wm wide and 3 mm long) were dissected from femoral
arteries and freed of connective tissue under binocular microscope
in normal physiological saline solution (PSS) containing (in mM)
NaCl 123, KCl 4.7, CaCl2 1.25, MgCl2 1.2, KH2PO4 1.2, NaHCO3
15.5 and D-glucose 5 gassed with 95% O2 and 5% CO2. The endothe-
lium was removed by gentle rubbing with a cotton swab. Then strips
were tied with silk ¢lament and suspended between the ¢ne tips of two
tungsten needles, one of which was connected to a force transducer
(FORT-10, World Precision Instruments, Sarasota, FL, USA). Before
starting experiments, strips were stimulated with 118 mM K PSS,
which was made by an equimolar substitution of KCl for NaCl, every
15 min until the maximal response was obtained. The contractile
responses were terminated by the immersion of dry ice-cold acetone
containing 10% (w/v) trichloroacetic acid (TCA) and 10 mM dithio-
threitol (DTT). Proteins were extracted in SDS-sample bu¡er contain-
ing 100 mM Tris^HCl pH 6.8, 50 mM DTT, 1% SDS, 15% glycerol
and 0.002% bromophenol blue and then subjected to SDS^PAGE,
followed by Western blot. For determination of MBS and MLC,
proteins separated on 5^20% gradient slab gel were transferred onto
nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). For CPI-17,
proteins were blotted onto polyvinyldi£uoride membrane (Bio-Rad,
Hercules, CA, USA). The membranes were blocked in Tris-bu¡ered
saline containing 5% non-fat milk and then incubated with primary
antibodies. The immune complexes of the primary antibodies were
Fig. 1. Dephosphorylation of phospho-CPI17 and phospho-MBS by
smooth muscle extract. Turkey gizzard was sonicated for 1 min
with bu¡er containing 50 mM Tris^Cl, pH 7.5, 250 mM sucrose, 60
mM KCl, 1% Triton X-100, 0.5% nonidate P40, 2 mM EGTA,
2 mM EDTA, 10 mg/l leupeptin, 0.1% 2-ME, and 0.1 mM phenyl-
methylsulfonyl £uoride. The resulting extract was used for the phos-
phatase assay. C, before dephosphorylation. A: E¡ect of okadaic
acid on dephosphorylation. 0.193 mg/ml gizzard extract containing
50 mM Tris^Cl, pH 7.0, 0.1 mM EGTA, 0.1% 2-ME, 0.3 mg/ml
BSA, 0.03% Brig-35, and various concentrations of okadaic acid
was incubated with each substrate for 10 min at 30‡C. MBS (3.3
Wg/ml, b), MBS phosphorylated at T641 (3.3 Wg/ml, 8), CPI17 at
Thr38 (66 Wg/ml, R), and MLC (83 Wg/ml, F). Error bars indicate
S.E.M. of three independent experiments. B: E¡ect of divalent cati-
ons on dephosphorylation. (3), without divalent cations; Ca, 0.2
mM CaCl2 ; Ca+Mn, 0.2 mM CaCl2 and 10 mM MnCl2 ; Mn, 10
mM MnCl2 ; Mg, 10 mM MgCl2. Error bars indicate S.D. (n = 3).
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detected with horseradish peroxidase-conjugated secondary antibodies
and chemiluminescence (Pierce, Rockford, IL, USA).
2.6. Other procedures
SDS^PAGE was performed according to Laemmli [33]. The West-
ern blot was carried out as described previously [31]. Protein concen-
trations were determined with the Bradford method [34] using BSA as
a standard.
3. Results
3.1. Dephosphorylation of MBS, CPI17 or MLC by smooth
muscle extracts
MBS of MLCP and CPI17 were phosphorylated by Rho-
kinase or PKCK, to the extent of 2.3 and 1.35 mol/mol, re-
spectively. These phosphorylated MLCP regulatory proteins
were used for the dephosphorylation experiment. In order to
identify the type of phosphatase responsible for the dephos-
phorylation of MBS and CPI17 in smooth muscle cells, we
examined the e¡ect of okadaic acid in the dephosphorylation
of these MLCP modulators by total smooth muscle extract
that contains all four types of the phosphatases [35,36]. The
IC50 of the dephosphorylation of MLC phosphorylated by
MLCK was 10 nM (Fig. 1), which is consistent with the
previous results [19,20]. The IC50 for CPI17 phosphorylated
at Thr38 was 1 nM, much lower than that of phosphorylated
MLC, suggesting that PP2A is a predominantly responsible
phosphatase for CPI17. While the majority of the CPI17
phosphatase activity was inhibited by okadaic acid, there
were residual phosphatase activities insensitive to okadaic
acid. To identify the okadaic acid insensitive phosphatases,
we examined the divalent cation sensitivity of the CPI17 phos-
phatases. The activity was insensitive to 0.2 mM Ca2 but
increased with 10 mM Mg2 (Fig. 1B), suggesting that
PP2C but not PP2B can dephosphorylate CPI17 at Thr38.
On the other hand, phosphorylated MBS was not signi¢cantly
dephosphorylated by smooth muscle extract (Fig. 1), suggest-
ing that MBS dephosphorylation is not a fast event in smooth
muscle. The lack of dephosphorylation of MBS was also con-
¢rmed by using phospho-Thr641-speci¢c antibodies (Fig. 1A).
The result indicated that the inhibitory phosphorylation site
of MBS, i.e. Thr641, is resistant to dephosphorylation by
protein phosphatases.
3.2. Dephosphorylation of MBS, and CPI17 by puri¢ed PP1c,
PP2Ac, PP2B and PP2C
To further study which types of phosphatases can dephos-
phorylate MBS and CPI17, puri¢ed PP1c, PP2Ac, PP2B or
PP2C were used for the dephosphorylation experiments. As
shown in Fig. 2A, MLC, but not CPI17 or MBS, is a good
substrate for PP1c. Recombinant PP1N, the catalytic subunit
of MLCP [9], also dephosphorylated MLC, but not CPI17
and MBS (not shown).
On the other hand, PP2Ac dephosphorylated CPI17 very
well and the dephosphorylation rate of CPI17 by PP2Ac was
about 10 times greater than that of MLC. MBS was highly
resistant to the dephosphorylation by PP2Ac, and the rate
was at least 100^500 times and 300^1000 times lower than
that of MLC and CPI17, respectively. To determine whether
M20 and/or PP1N a¡ect the dephosphorylation of MBS by
PP2Ac, we reconstituted MBS with recombinant PP1N and
Fig. 2. Dephosphorylation of phosphorylated MBS and CPI17 by various types of protein phosphatases. The assay was done as described in
Section 2. 1 U of the activity is de¢ned as the amount of enzyme that catalyzes the release of 1 Wmol of phosphate of MLC in 1 min. MBS
(3.3 Wg/ml, b, a), CPI17 (66 Wg/ml, R, O), MLC (83 Wg/ml, F). A: PP1c: 0.2 mU/ml (closed symbol) or 3 mU/ml (open symbol) of PP1c was
used. B: PP2Ac: 0.4 mU/ml (closed symbol) or 20 mU/ml (open symbol) of PP2Ac was used. C: PP2B: 0.15 mU/ml of PP2B was used.
D: PP2C: 0.6 mU/ml of PP2C was used. Error bars indicate S.E.M. of three independent experiments.
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M20 to form holoenzyme. M20 and PP1N had almost no e¡ect
on the dephosphorylation at the Thr641 site of MBS (not
shown).
PP2B could dephosphorylate CPI17 and MBS (Fig. 2C).
However, PP2B would not be a dominant phosphatase for
MBS and CPI17, since Ca2 had no e¡ect on dephosphory-
lation of CPI17 and MBS by total cell extract. PP2C dephos-
phorylated CPI17 well but failed to dephosphorylate MBS
(Fig. 2D). Dephosphorylation of MBS could not be detected
even with a 250-fold higher concentration of PP2C (not
shown). The result is consistent with that of Fig. 1 and sug-
gests that PP2C play a role in dephosphorylating CPI17.
Taken together, our results showed that MBS is highly re-
sistant to protein phosphatases. CPI17 is predominantly de-
phosphorylated by PP2Ac and PP2C. However, it is antici-
pated that PP2A is the most likely physiological phosphatase
since the majority of the CPI17 phosphatase activity in total
tissue extract was inhibited by okadaic acid with nanomolar
range.
Fig. 3. Dephosphorylation of MBS at Thr641 and Thr799 by vari-
ous types of protein phosphatases. The assay was done as described
in Section 2. PP1c (3 mU/ml, 30‡C), PP2Ac (20 mU/ml, 20‡C), and
PP2B (0.15 mU/ml, 30‡C) were used. MBS phosphorylation (b),
phospho-Thr641 of MBS (R) and phospho-Thr799 of MBS (F).
Total extent of phosphorylation was estimated by 32P-incorporation.
The phosphorylation of the Thr641 and Thr799 are determined by
Western blot using the phosphorylation site-speci¢c antibodies. Sim-
ilar results have been obtained from three independent experiments.
Inset: Time course of the dephosphorylation of MBS determined by
Western blot and autoradiography. Times (min) after adding the
phosphatases were indicated on the top of the panel. The relative
amount of the protein (MBS) loaded onto the gel was determined
by Western blot using anti-MBS monoclonal antibody. M indicates
the presence of 1 WM microcystin LR.
Fig. 4. E¡ect of phospholipids on the dephosphorylation at Thr641
of MBS and Thr38 of CPI17. The assay was done as described in
Section 2. PP1c (3 mU/ml, 30‡C, 20 min), PP2Ac (20 mU/ml, 20‡C,
3 min), PP2B (0.15 mU/ml, 30‡C, 30 min) or PP2C (0.6 mU/ml,
30‡C, 30 min) was used for the assay. A: E¡ect of PS on dephos-
phorylation of MBS. PP2Ac (a), PP2B (O). B: E¡ect of phospho-
lipids on the dephosphorylation at MBS. The assay was performed
with PS (b), AA (R), LPA (F), diacylglycerol (DAG; a), or PI
(E). C: E¡ect of AA on dephosphorylation of MBS (open symbols)
and CPI17 (closed symbols). The assay was performed with PP1c
(7), PP2Ac (b, a), PP2B (R, O), or PP2C (F).
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3.3. Determination of site-speci¢c dephosphorylation of MBS
by various protein phosphatases
It is known that MBS has two major phosphorylation sites,
i.e. Thr641 and Thr799 [11], among which the former site is
responsible for the downregulation of MLCP activity. We
compared the rate of dephosphorylation of each site by var-
ious phosphatases using site-speci¢c phospho-MBS antibod-
ies. The rate of dephosphorylation of Thr641 was signi¢cantly
slower than that of Thr799 site for all three types of phospha-
tases (Fig. 3). The results show that Thr641, the inhibitory
phosphorylation site of MBS, is highly resistant to dephos-
phorylation.
3.4. E¡ect of phospholipids on the dephosphorylation of MBS
by protein phosphatases
It is known that MBS localizes on plasma membrane in the
meta-phase of mitotic cells [37], yet the e¡ect of the membrane
binding on the phosphorylation/dephosphorylation cycle of
MBS is unknown. We examined whether phospholipids a¡ect
the dephosphorylation of MBS (Fig. 4). Among various phos-
pholipids tested, lysophosphatidic acid (LPA) and phosphati-
dylserine (PS) were most e¡ective for the inhibition of the
dephosphorylation of MBS by PP2Ac. The inhibition was
not observed for MLC as a substrate (not shown) suggesting
that the e¡ect is not directly due to the enzyme but rather due
to the change in MBS structure, presumably blocking the sites
by phospholipid binding. Consistently, the similar inhibition
of dephosphorylation of MBS by PS was observed for PP2B.
On the other hand, a physiological concentration of arachi-
donic acid (AA) also inhibited MBS dephosphorylation. How-
ever, the inhibition was not speci¢c to MBS but the dephos-
phorylation of CPI17 and MLC was also inhibited by AA at
the similar concentration (not shown), suggesting that AA
directly inhibits PP2Ac activity.
3.5. Dephosphorylation of MBS and CPI17 in intact smooth
muscle ¢ber
The above results suggest that the phosphorylation of MBS
at Thr641, a site responsible for the downregulation of
MLCP, is resistant to dephosphorylation by protein phospha-
tases while the phosphorylation at Thr38 of CPI17, a site
critical to the phosphatase inhibitory activity, is readily de-
phosphorylated in vitro. A critical question is whether this is
the case in vivo. To address this question, we examined the
e¡ect of removal of agonist on the phosphorylation of MBS
and CPI17 in intact smooth muscle ¢ber. Rabbit femoral ar-
tery was stimulated by histamine as an agonist, then the ago-
nist was removed (Fig. 5). The force was promptly decreased
after the agonist was removed and this was accompanied with
a decrease in MLC phosphorylation (Fig. 5A,B). During the
decrease in force due to the removal of the agonist, CPI17
phosphorylation at Thr38 was markedly decreased. In con-
trast, the phosphorylation of MBS at Thr641 was hardly de-
creased during the decrease in force in intact smooth muscle
¢ber. The results are consistent with those obtained under in
vitro conditions and support the idea that while CPI17 is
susceptible to dephosphorylation by protein phosphatases,
phosphorylation of MBS at Thr641 is resistant to the dephos-
phorylation reaction.
4. Discussion
The present study clearly demonstrates that phosphorylated
MBS is highly resistant to dephosphorylation by protein
phosphatases, especially at Thr641, which is responsible for
the inhibition of MLCP. This implies that MBS, once phos-
phorylated, remains for a prolonged time in the phosphory-
lated form. Therefore, it is plausible that MBS phosphoryla-
tion-based regulation of MLCP is more suitable for the long-
term regulation of MLCP, thus the regulation of MLC phos-
phorylation, rather than the acute regulation such as smooth
muscle contraction/relaxation cycle.
On the other hand, phosphorylated CPI17 at Thr38 is read-
ily dephosphorylated by smooth muscle cell extract containing
various protein phosphatases. The present results suggest that
predominant CPI17 phosphatases are PP2A and PP2C. Sig-
ni¢cant portions of CPI17 phosphatase activity in total tissue
extract were inhibited by nanomolar concentration of okadaic
acid. While PP4 and PP5 activities are also inhibited by the
similar concentration range of okadaic acid, they are less
likely to be responsible for the dephosphorylation of CPI17
since both PP4 and PP5 are predominantly found in the nu-
cleus [38,39]. The rate of dephosphorylation of CPI17 by these
phosphatases is quite fast (even faster than the dephosphor-
ylation of isolated MLC). It was shown recently that CPI17 is
phosphorylated in intact and permeabilized smooth muscle
strip after agonist stimulation [30]. Although the stability of
the phosphorylated CPI17 in cells has not been determined
yet, the present result suggests that the phosphorylated CPI17
in cells would be readily dephosphorylated after the kinase
activating signaling is ceased. Therefore, the present study
supports the notion that CPI17 phosphorylation plays a role
in regulating MLCP in MLC phosphorylation during the ag-
onist-induced contraction^relaxation cycle.
Recently, new MBS binding proteins were found in addi-
tion to myosin (e.g. moesin, which a¡ects microvilli formation
and adducin, which a¡ects membrane ru¥ing and cell motil-
Fig. 5. Changes in the CPI-17 and MBS phosphorylation in intact
smooth muscle after removal of the agonist. A: Representative re-
cording of change in the force of intact rabbit femoral artery in-
duced by histamine. Rabbit femoral artery was pre-contracted by
histamine (10 WM) and when the force reached steady state (3 min
after the application of histamine), histamine was removed by wash-
ing out with PSS. B: Phosphorylation of MBS, CPI-17 and MLC
in intact smooth muscle. Smooth muscle strips during the contrac-
tion by histamine (30 s, 1 min and 3 min after histamine stimu-
lation) and 10 min after the removal of histamine were immersed in
TCA/acetone to stop the reaction and then subjected to Western
blotting. The same amount of proteins (10 Wg) were applied to
SDS^PAGE. Note that the signals of anti-MBS and anti-CPI17 that
recognize the target proteins regardless of their phosphorylation
states were the same among the lanes indicating that the same
amount of proteins was loaded.
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ity). The localization of these proteins is regulated by their
phosphorylation [40,41], raising a possibility that change in
the MLCP activity via MBS phosphorylation may play a
role in regulating the localization of these MBS binding pro-
teins. MBS is also found in the nucleus in addition to cyto-
plasm [42]. Distinct MBS phosphatases might be responsible
for the dephosphorylation of MBS that binds to di¡erent
target proteins.
An interesting ¢nding is that MBS dephosphorylation is
signi¢cantly inhibited by phospholipids. It has been shown
that MBS has a high a⁄nity for acidic phospholipids such
as PS or PA and others via its C-terminal region [37]. Inter-
estingly, the order of inhibitory potency of MBS dephosphor-
ylation by the various phospholipids (Fig. 4) coincides with
the order of the binding a⁄nities between MBS and these
phospholipids [37]. The result suggests that the binding of
MBS to phospholipids occludes the phosphorylated sites
thus preventing the dephosphorylation by the phosphatases.
The present results also suggest that the binding of MBS to
membrane would preserve the phosphorylated state for a pro-
longed time. It has been shown that MBS localized at the
membrane ru¥ing sites in MDCK cells has an increased level
of phosphorylation after HGF (hepatocyte growth factor)
stimulation [42]. Since the membrane ru¥ing sites represent
a highly increased membrane surface, and thereby an in-
creased amount of phospholipids present, this previous ¢nd-
ing is consistent with the present ¢nding that phospholipids
prevent the dephosphorylation of MBS.
On the other hand, AA inhibits the dephosphorylation of
CPI17 by PP2A via direct inhibition of PP2A activity. It has
been shown that AA induces the Ca2-sensitization of smooth
muscle contraction [43]. The AA e¡ect in Ca2-sensitization
was originally proposed to be due to the dissociation of
MLCP holoenzyme and resulting inactivation of the enzyme.
The present study raises another possibility that AA induces
Ca2-sensitization via inhibition of CPI17 dephosphorylation.
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